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ABSTRACT
In the recent years important biomarkers have emerged as tools for diagnosis and risk stratification in car-
diovascular diseases. Such markers are B- type natriuretic peptide (BNP) and N- terminal B-type natriuret-
ic peptide (NT-proBNP).
Peripheral blood for the serum levels of NT-proBNP was taken from patients with STEMI before PCI and 24-
48 hours after the onset of the symptoms of myocardial infarction. Three of the samples from all 53 turned 
out to be positive to NT-proBNP concentration on Day 0. On day 1 there was a significant elevation of the 
positive samples 11 from 53 patients (20.7%) (p=0.01). All patients with STEMI and elevated serum levels of 
NT-proBNP have left ventricular ejection fraction <50%. 
Our results imply that NT- proBNP level and its increase in the serum may be used as a biomarker for the se-
verity of the ischemic heart disease.
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INTRODUCTION
The prevalence of acute and chronic ischemic 
heart disease and heart failure reaches up to 8% in 
the Western countries. Heart failure and acute myo-
cardial infarction (AMI) remain the leading causes 
of morbidity and mortality in the developed coun-
tries (1). 
It has been proven, that the most effective treat-
ment method of one of the forms of ischemic heart 
diseases - AMI is immediate reperfusion achieved 
through percutaneous coronary intervention (PCI). 
This method allows early restoration of blood flow in 
the infarct- related artery (IRA) and is the principal 
mechanism by which reperfusion therapy improves 
the outcome in patients with AMI (2,3).
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Nevertheless, patients with AMI are found to 
have a 10% higher risk of death and 25 % higher risk 
of developing heart failure within the first year of the 
ischemic attack (4).
In the recent years important biomarkers have 
emerged as tools for diagnosis and risk stratification 
in cardiovascular diseases. Such markers are B-type 
natriuretic peptide (BNP) and N-terminal B-type 
natriuretic peptide (NT-proBNP). Both molecules 
are constantly released and can be detected in blood. 
The main stimulus for their secretion is myocardi-
al wall stress. These peptides are released predom-
inantly from the myocardium in response to myo-
cyte stretch.They are produced from a prohormone, 
which is split into BNP and NT-proBNP (5). Accord-
ing to the European Society of Cardiology they are 
recommended to be measured in diagnosing chronic 
heart failure (6).
Several reports, however, indicate that BNP and 
NT-proBNP were increased in the serum of patients 
with acute myocardial infarction (AMI) and showed 
usefulness in detecting left ventricular dysfunction 
(7-11).
The goal of our study was to examine the 
predicitive value of the serum levels of NT-pro BNP 
in patients with ST-elevation myocardial infarction 
(STEMI) treated with percutaneous coronary inter-
vention (PCI) after a median follow-up of 12 months.
MATERIALS AND METHODS
Ethics Statement
All procedures were approved by the Scientific 
Research Ethics Commitee of the Medical Universi-
ty of Varna. 
The current study was conducted at the St. Ma-
rina University Hospital, Varna after an informed 
consent form (ICF) from all study participants.
Patient Selection
From October, 2014 to April, 2016, blood sam-
ples were taken from 53 patients with STEMI . 
Patients were treated with percutaneous cor-
onary intervention (PCI) within the first 12 hours 
of the onset of clinical manifestation and had post-
procedure Thrombolysis in Myocardial Infarction 
(TIMI) flow grade 3.
Serum levels of NT-proBNP were measured 
upon admission on Day 0 (<12 hours from the on-
set of the symptoms) and on Day 1 (24-48 hours after 
the onset of symptoms of myocardial infarction). The 
time of the onset of symptoms and the first blood test 
is less than 1 hour for 2 patients (3.9%), 1-3 hours - 19 
patients (37.2%), 3-6 hours - 20 patients (39.2%) and 
6-12 hours - 12 patients (23.5%).
Inclusion criteria for the patients with myocar-
dial infarction in the current study were: chest pain 
with significant (minimum 2mm) ST-segment el-
evation in at least 2 contiguous electrocardiogram 
(ECG) leads and/or a significant increase in cardi-
ac markers (troponin I>0.2 ng/ml), <12 hours after 
the onset of symptoms to primary PCI, all patients 
underwent cardiac catheterization and were treat-
ed with primary coronary angioplasty and stent re-
placement. Exclusion criteria were clinical or labora-
tory evidence of current infection, other inflamma-
tory or oncologic disease.
Echocardiography
Left ventricular ejection fraction (LVEF) was 
evaluated and recorded by a biplane method of disks 
(Simpson’s rule) in accordance with the European 
Association of Cardiovascular Imaging.
Measurement of the Levels of NT- proBNP in 
the Serum
Peripheral blood sample from the patients with 
STEMI was taken before PCI and again 24-48 h after 
the onset of symptoms. The amount of every blood 
sample was 8 ml divided into 2 tubes and within 
15 minutes centrifuged at 2500 for 20 min. Serum 
was frozen and stored at 80C. Concentration of NT- 
proBNP was determined using an ELISA (CUSA-
BIO, Wuhan, China) according to the manufactur-
er’s instructions.
Statistical Analysis
Statistical analysis was carried out by SPSS Sta-
tistics v.23 using descriptive statistics.
Categorial features were summarized with fre-
quencies and percentages. Variables were reported as 
mean ± standard deviation (SD). Wilcoxon paired 
test was used.
RESULTS
Demographic Characteristics and Follow-Up 
of the Patients
In the group of patients with STEMI men were 
56.6%, while women - 43.4%. The average age of the 
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patients with STEMI was 63.9±12.9 with the mini-
mum age being 29 and the maximum - 85 years.
Demographic characteristics of the patients 
with STEMI are shown in Table 1.
Median follow-up of the STEMI patients was 12 
months. After the follow-up, 5 STEMI patients died 
from cardiac causes and 4 STEMI patients were fur-
ther hospitalized due to symptoms of heart failure.
Serum Levels of NT- proBNP in Patients with 
STEMI
Peripheral blood for the serum levels of NT-
proBNP was taken from patients with STEMI before 
PCI and 24-48 hours after the onset of the symptoms 
of myocardial infarction. Three of the samples from 
all 53 turned out to be positive to NT-proBNP con-
centration on Day 0. On Day 1 there was a significant 
elevation of the positive samples (Figure 1 ) - 11 from 
53 patients (20.7%) (p=0.01). From those 11 patients, 
6 were with two –vessel coronary artery disease, 2 
patients - with three vessel coronary artery disease 
and 3 patients with single-vessel coronary artery dis-
ease. Three of these patients died during follow-up.
Figure 1 shows the serum levels of NT-proBNP 
in patients with ST-elevation myocardial infarction 
(STEMI) on Day 0 and Day 1. A value of p<0.05 is 
considered statistically relevant.
All patients with STEMI and elevated serum 
levels of NT- proBNP have left ventricular ejection 
fraction <50%. There is a significant correlation be-
tween the serum levels of NT-proBNP and the serum 
levels of RIPK3 - a marker for necroptosis (r=0.629, 
p=0.038) and a weak correlation between NT-proB-
NP and Troponin I (r=0.296, p=37).
DISCUSSION
In our study we confirm the results that patients 
with STEMI 24-48 h after the onset of the symptoms 
and ejection fraction (EF <50%) showed increased 
serum levels of NT-proBNP. According to the Euro-
pean Society of Cardiology the N-terminal part of 
the pro – B type natriuretic peptide (NT-proBNP) is 
recommended to be measured in diagnosing heart 
failure (6). NT-proBNP plasma concentrations also 
typically increased in patients with asymptomatic or 
symptomatic left ventricular dysfunction are also as-
sociated with coronary artery disease and myocar-
dial ischemia (12). NT-proBNP is mainly released 
from myocytes in the cardiac ventricles as a result of 
wall tension and stretch in response to stimuli such 
as ischemia or cytokine secretion. The role and par-
ticipation of this molecule in different cardiovascular 
diseases has been discussed well (13).
In a study measuring the concentration of NT-
proBNP in patients with normal or slightly decreased 
EF this marker was shown to correlate with left ven-
tricular systolic impairment and left ventricular sys-
tolic ejection fraction <40%.
In a study that we performed we also exam-
ined RIPK3 – a novel regulator of programmed cell 
death in healthy people and its correlation with NT 
proBNP (14). This study included the same 53 pa-
tients with STEMI. Programmed necrosis mediat-
ed by RIPK3 – a regulator of programmed cell death 
has recently been defined as a novel mechanism of 
cell death with major functional importance in sev-
eral organs, including the heart (15). RIPK3 is also 
responsible for generation of reactive oxygen species, 
which is supposed to be another mechanism for or-
gan damage due to myocardial ischemia (16). Our re-
sults suggest that serum level of RIPK3 is significant-
Demographic parameters STEMI Signicance
Age, yrs. 63.9±12.9 p=0.32
Male, % 57.4 p=0.43
Hypertension, % 100 -
Diabetes, % 15.7 p=0.68
Hypercholesterolemia, % 70.2 p=0.13
Table 1. Baseline characteristics of STEMI patients  
(ST- elevation myocardial infarction)
Fig. 1. Serum levels of NT-proBNP in patients with ST-ele-
vation myocardial infarction (STEMI) on Day 0 and Day 1
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ly increased 24 hours after the onset of symptoms. 
There is a strong correlation between the serum lev-
els of RIPK3 and NT-proBNP.
Serum levels of NT-proBNP are increased after 
24-48 hours after the onset of symptoms of myocar-
dial infarction and may define the degree of myocyte 
injury. Furthermore, our results imply that the NT-
proBNP level and its increase in the serum may be 
used as a biomarker for the severity of the ischemic 
heart disease.
New studies, however, are necessary to define 
the exact role of NT-proBNP for risk stratification 
and prognosis in patients with STEMI.
CONCLUSION 
In summary our results suggest that patients 
with STEMI show increased serum levels of NT-
proBNP 24-48 hours after the onset of clinical mani-
festation of myocardial infarction. NT-proBNP may 
have the potential as a new biomarker to evaluate the 
prognosis in patients with STEMI.
REFERENCES
1. Gaziano, T., et al., Cardiovascular Disease, in Dis-
ease Control Priorities in Developing Countries, 
D.T. Jamison, et al., Editors. 2006: Washington 
(DC).
2. Andersen, H.R., et al., A comparison of coronary 
angioplasty with fibrinolytic therapy in acute myo-
cardial infarction. N Engl J Med, 2003. 349(8): p. 
733-42.
3. Boden, W.E., K. Eagle, and C.B. Granger, Reperfu-
sion strategies in acute ST-segment elevation myo-
cardial infarction: a comprehensive review of con-
temporary management options. J Am Coll Cardi-
ol, 2007. 50(10): p. 917-29.
4. Keeley, E.C., J.A. Boura, and C.L. Grines, Primary 
angioplasty versus intravenous thrombolytic ther-
apy for acute myocardial infarction: a quantita-
tive review of 23 randomised trials. Lancet, 2003. 
361(9351): p. 13-20.
5. Morita, E., et al., Increased plasma levels of brain 
natriuretic peptide in patients with acute myocar-
dial infarction. Circulation, 1993. 88(1): p. 82-91.
6. Swedberg, K., et al., Guidelines for the diagnosis 
and treatment of chronic heart failure: executive 
summary (update 2005): The Task Force for the Di-
agnosis and Treatment of Chronic Heart Failure of 
the European Society of Cardiology. Eur Heart J, 
2005. 26(11): p. 1115-40.
7. Nagaya, N., et al., Plasma brain natriuretic peptide 
is a biochemical marker for the prediction of pro-
gressive ventricular remodeling after acute myocar-
dial infarction. Am Heart J, 1998. 135(1): p. 21-8.
8. Talwar, S., et al., Profile of plasma N-terminal 
proBNP following acute myocardial infarction, 
correlation with left ventricular systolic dysfunc-
tion. Eur Heart J, 2000. 21(18): p. 1514-21.
9. Groenning, B.A., et al., Detection of left ventricular 
enlargement and impaired systolic function with 
plasma N-terminal pro brain natriuretic peptide 
concentrations. Am Heart J, 2002. 143(5): p. 923-9.
10. Galvani, M., et al., N-terminal pro-brain natriuret-
ic peptide on admission has prognostic value across 
the whole spectrum of acute coronary syndromes. 
Circulation, 2004. 110(2): p. 128-34.
11. Bazzino, O., et al., Relative value of N-terminal pro-
brain natriuretic peptide, TIMI risk score, ACC/
AHA prognostic classification and other risk mark-
ers in patients with non-ST-elevation acute cor-
onary syndromes. Eur Heart J, 2004. 25(10): p. 
859-66.
12. Kim, H., et al., Incremental prognostic value of C-
reactive protein and N-terminal proB-type natri-
uretic peptide in acute coronary syndrome. Circ J, 
2006. 70(11): p. 1379-84.
13. Szadkowska, I., et al., The relationship between ear-
ly recanalization and serum NT-proBNP levels in 
patients with a first ST-segment elevation myocar-
dial infarction treated with primary coronary an-
gioplasty. Acta Cardiol, 2007. 62(5): p. 479-84.
14. Kashlov, J.K., et al., Serum levels of RIPK3 and tro-
ponin I as potential biomarkers for predicting im-
paired left ventricular function in patients with 
myocardial infarction with ST segment elevation 
and normal troponin I levels prior percutaneous 
coronary intervention. Biosci Trends, 2016. 10(4): 
p. 294-9.
15. Linkermann, A. and D.R. Green, Necroptosis. N 
Engl J Med, 2014. 370(5): p. 455-65.
16. Zhao, H., et al., Role of necroptosis in the patho-
genesis of solid organ injury. Cell Death Dis, 2015. 
6: p. e1975.
